The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
NLRP3 inflammasome activation drives tau pathology
Open accessAbstract
Alzheimer’s disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1. The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2. Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice3, the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer’s disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation. The authors show that NLRP3 inflammasome is activated in microglia of patients with fronto-temporal dementia and in a mouse model of tau pathology, and that the loss of NLRP3 inflammasome function decreases tau pathology and improves cognition in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The NLRP3-ASC inflammasome mechanisms contributing to increased beta-amyloids and tau are thought to be a combination of kinases and phosphatases involved in tau phosphorylation [96] through the production of IL-1 beta.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Ising et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, several cytokines, including IL-1β and IL-6, can directly induce tau phosphorylation in vitro, thus potentially contributing to the development of tau pathology.54”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Research by Ising et al. suggests that tau proteins can activate the NLRP3 inflammasome, which then promotes excessive tau phosphorylation and aggregation by affecting specific tau kinases and phosphatases.252”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [252]
The cited source says what the claim attributes to it.
In the citing paper
“In turn, the NLRP3 inflammasome is essential for the development and progression of Aβ pathology in mice29 and may drive tau pathology through Aβ-induced microglial activation30.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, microglia could also drive tau spreading and toxicity by promoting neuroinflammation, such as activating NACHT-, LRR- and pyrin (PYD)-domain-containing protein 3 (NLRP3) inflammasome155 or inducing NF-kB signaling.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [155]
The cited source says what the claim attributes to it.
In the citing paper
“Tau oligomers and monomers can also activate NLRP3 inflammasomes, further perpetuating microglial activation [162] and potential progression of tau pathology.”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“The NLRP3 inflammasome has a bidirectional relationship with AD-related tau pathology as well.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“In Tau22 mice, ablation of Nlrp3 or Asc reduced levels of hyperphosphorylated tau and tau aggregates and rescued tau-induced spatial memory deficits [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
In the citing paper
“Studies have demonstrated important roles of the NLRP3 inflammasome in aging and age-related diseases, such as atherosclerosis metabolic syndrome, type 2 diabetes, and Alzheimer’s disease (81–83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“For example, in AD and frontotemporal dementia, neuroinflammation and microglia activation potentiate the spreading of pathological tau neurofibrillary tangles (83, 175).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“In AD, this relationship may be mediated by NLRP3 inflammasome activation in microglia, a process that activates tau kinases (e.g., GSK-3β and CaMKII-α) and results in tau hyperphosphorylation (83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“The knockout of ASC or NLRP3 ameliorates AD‐like brain pathology in animal models. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“The activation of the NLRP3 inflammasome drives tau pathology. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“Inflammaging can drive tau pathology and neurodegeneration in AD by impairing the clearance of Aβ peptides, altering BBB integrity, and affecting the synaptic functions. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“A recent study shows that NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome activation induces tau hyperphosphorylation and aggregation through modulating tau kinases and phosphatases [159].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [159]
In the citing paper
“In the CNS, inflammasome activation has been mainly linked to neuroinflammatory conditions. As example, it has an essential role in the progression of several neurological disorders like MS, AD, PPD, and NPS (132, 193–197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“In general, patients affected by tauopathies showed elevated levels of cleaved caspase-1 and ASC and mature IL-1β in the cortex (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Injecting brain homogenates from APP/PS1 or wild-type mice into the hippocampus of Tau22 mice, induced tau hyperphosphorylation in the hippocampus of Tau22 wild-type but not Tau22/Pycard−/− or Tau22/Nlrp3−/− deficient mice”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“suggesting that NLRP3 activation is upstream the Aβ-tau cascade and tau pathology (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Consistent with this, Tau22 mice lacking ASC or NLRP3 expression had lower levels of aggregated and hyperphosphorylated tau in the hippocampus, and their typical spatial memory deficits were rescued (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Also, Tau22 mice, another model of AD and other tauopathies, had increased levels of cleaved caspase-1 and ASC in their brain at the age of 11 months compared to their 3-month-old counterparts.”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Further, activated microglia promote tau phosphorylation and aggregation by activation of the NLRP3 (nucleotide binding oligomerisation domain (NOD)-, leucine-rich repeat (LRR)- and pyrin domain-containing protein 3) inflammasome in response to amyloid-β [22,23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Further, there is evidence tauopathy is driven by NLRP3 inflammasome activation in microglia in response to amyloid-β [23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“ROS from NOX4 also contribute to activation of the NLRP3 inflammasome, a driver of both amyloid-β [156] and tau [23] pathology.”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Growing evidence indicates that Aβ accumulation stimulates tau phosphorylation and fibrillary tangle formation, leading to the process of neurodegeneration.112–114”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [112]
In the citing paper
“In particular, microglial NLRP3 has been shown to be a major driver of amyloid beta and tau toxicity in AD, suggesting its activation has important implications for disease progression (Halle et al, 2008; Venegas et al, 2017; Ising et al, 2019).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Ising et al, 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
Self-citationThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983
Self-citationInflammasome signalling in brain function and neurodegenerative disease
Heneka, M. T., McManus, R. M., & Latz, E. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0055-7 · Cited by 836
Self-citationCanonical Nlrp3 Inflammasome Links Systemic Low-Grade Inflammation to Functional Decline in Aging
Youm, Y.-H., Grant, R. W., McCabe, L. R., Albarado, D. C., Nguyen, K. Y., Ravussin, A., Pistell, P., Newman, S., Carter, R., Laque, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.010 · Cited by 674
Cited by
Sorted by citations
Items 701–800 of 1,003
Wang, Y., Jiang, R., Li, M., Wang, Z., Yang, Y., & Sun, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230784 · Cited by 18
Zhang, S., Li, M., Chang, L., Mao, X., Jiang, Y., Shen, X., Niu, K., Lu, X., Zhang, R., Song, Y., et al. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1320202 · Cited by 15
Self-citationMechanisms with network pharmacology approach of Ginsenosides in Alzheimer's disease
He, S., Shi, J., Chai, H., Ma, L., Pei, H., Zhang, P., Shi, D., & Li, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26642 · Cited by 17
Risen, S. J., Kusick, B. R., Sharma, S., Gilberto, V. S., Brindley, S., Aguilar, M., Brown, J. M., McGrath, S., Chatterjee, A., Moreno, J. A., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00068 · Cited by 15
Kaur, B., Biby, S., Namme, J. N., More, S., Xu, Y., & Zhang, S. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2024.10.004 · Cited by 15
Self-citationMicroglial Modulation in Alzheimer’s Disease: Central Players in Neuroinflammation and Pathogenesis
Hussain, M. S., Khan, Y., Fatima, R., Maqbool, M., Ramalingam, P. S., Khan, M. G., & Bisht, A. S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050364292250113063513 · Cited by 15
Zhu, K., Pieber, M., Han, J., Blomgren, K., Zhang, X., Harris, R. A., & Lund, H. (2020) · Glia · doi:10.1002/glia.23794 · Cited by 16
Cadar, D., Jellinger, K. A., Riederer, P., Strobel, S., Monoranu, C., & Tappe, D. (2021) · Microorganisms · doi:10.3390/microorganisms9081716 · Cited by 16
Zhou, X., Kumar, P., Bhuyan, D. J., Jensen, S. O., Roberts, T. L., & Münch, G. W. (2023) · Biomolecules · doi:10.3390/biom13111568 · Cited by 17
Mandal, S., Ramesh, M., & Govindaraju, T. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02158 · Cited by 14
Rubio, A. D., Hamilton, L. L., Bausch, M., Jin, M., Papetti, A. V., Jiang, P., & Yelamanchili, S. V. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10181-x · Cited by 17
Bettcher, B. M., de Oliveira, F. F., Willette, A. A., Michalowska, M. M., Machado, L. S., Rajbanshi, B., Borelli, W. V., Tansey, M. G., da Rocha, A. S., Suryadevara, V., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03432-4 · Cited by 16
Yin, L., Liu, Q., Jia, Z., & Guo, B. (2025) · Advanced Exercise and Health Science · doi:10.1016/j.aehs.2025.05.004 · Cited by 17
Li, B., Wang, L., Yan, X., Tang, Z., Wang, Y., Sun, T., & Qi, X. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03506-3 · Cited by 15
Sabbagh, M. N., Cummings, J. L., Ballard, C. G., van der Flier, W. M., Heneka, M. T., Holst, J. J., Knudsen, L. B., Salloway, S., Tansey, M. G., & Drucker, D. J. (2025) · Nature Aging · doi:10.1038/s43587-025-01029-3 · Cited by 15
Self-citationDagla, I., Gkikas, F., Gikas, E. E., & Tsarbopoulos, A. (2026) · Cells · doi:10.3390/cells15030295 · Cited by 16
Immunity in Alzheimer’s disease: From mechanisms to therapies
Chen, X., Holtzman, D. M., & Colonna, M. (2026) · Immunity · doi:10.1016/j.immuni.2026.02.004 · Cited by 18
TRIMs: Generalists Regulating the NLRP3 Inflammasome Signaling Pathway
Deng, N.-H., Zhou, Z., Liu, H., Tian, Z., Wu, Z.-F., Liu, X.-Y., Xiong, W., Zuo, W., & Jiang, Z.-S. (2022) · DNA and Cell Biology · doi:10.1089/dna.2021.0943 · Cited by 14
Retina-to-brain spreading of α-synuclein after intravitreal injection of preformed fibrils
Pérez-Acuña, D., Rhee, K. H., Shin, S. J., Ahn, J., Lee, J., & Lee, S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01575-0 · Cited by 14
Jiang, S., Tian, T., Li, W., Liu, T., Wang, C., Hu, G., Du, R., Liu, Y., & Lu, M. (2023) · EMBO Reports · doi:10.15252/embr.202357101 · Cited by 13
Effect of General Anesthetic Agents on Microglia
Yang, Y., Hang, W., Li, J., Liu, T., Hu, Y., Fang, F., Yan, D., McQuillan, P. M., Wang, M., & Hu, Z. (2023) · Aging and Disease · doi:10.14336/ad.2023.1108 · Cited by 15
Lu, J., He, A.-X., Jin, Z.-Y., Zhang, M., Li, Z., Zhou, F., Ma, L., Jin, H.-M., Wang, J., & Shen, X. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01223-2 · Cited by 14
Srinivasan, S., Kancheva, D., Ren, S. D., Saito, T., Jans, M., Boone, F., Vandendriessche, C., Paesmans, I., Maurin, H., Vandenbroucke, R. E., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1323409 · Cited by 16
Emerging role of mesenchymal stem cells-derived extracellular vesicles in vascular dementia
Liu, Z., Cheng, L., Zhang, L., Shen, C., Wei, S., Wang, L., Qiu, Y., Li, C., Xiong, Y., & Zhang, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1329357 · Cited by 15
Complement receptor 4 mediates the clearance of extracellular tau fibrils by microglia
Yoo, C. J., Choi, Y., Bok, E., Lin, Y., Cheon, M., Lee, Y., & Kim, J. (2024) · FEBS Journal · doi:10.1111/febs.17150 · Cited by 16
The ASC inflammasome adapter governs SAA-derived protein aggregation in inflammatory amyloidosis
Losa, M., Emmenegger, M., Rossi, P. D., Schürch, P. M., Serdiuk, T., Pengo, N., Capron, D., Bieli, D., Bargenda, N., Rupp, N. J., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00107-0 · Cited by 15
Li, L.-J., Sun, X., Huang, Y., Lü, S., Xu, Y., Yang, J., Xie, X.-X., Zhu, J., Niu, X., Wang, D., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00427-8 · Cited by 15
Yassaghi, Y., Nazerian, Y., Ghasemi, M., Nazerian, A., Sayehmiri, F., Perry, G. L., & Pourbadie, H. G. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18554 · Cited by 15
Higher plasma soluble TREM2 correlates with reduced cerebral tau accumulation in Alzheimer’s disease
Lan, G., Li, A., González‐Ortiz, F., Lv, J., Ran, W., Cai, Y. Q., Sun, P., Liu, L., Yang, J., Zhang, L., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02976-4 · Cited by 16
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
Dujardin, P., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.004 · Cited by 14
Paasila, P. J., Davies, D., Sutherland, G. T., & Goldsbury, C. S. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-2845 · Cited by 16
NLRP3 inflammasome activation implicated in tau pathology
Lemprière, S. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0299-5 · Cited by 13
Lin, Y., Yoo, J. M., Li, D., Heo, Y., Okumura, M., Won, H., Vendruscolo, M., Lim, M. H., & Lee, Y. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00507-3 · Cited by 16
NLRP3 Inflammasome: A New Target for the Treatment of CVD and Depression Comorbidity
Chen, C., Zhang, S., Sheng, M., & Shao, W. (2025) · Mediators of Inflammation · doi:10.1155/mi/4330574 · Cited by 16
Self-citationLysosomes as hubs of metabolic sensing and cellular homeostasis
Jain, A., & Zoncu, R. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.01.011 · Cited by 15
Revisiting the relationship between complement and ulcerative colitis
Ma, Y., Zhang, K., Wu, Y., Fu, X., Liang, S., Peng, M., Guo, J., & Liu, M. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13329 · Cited by 13
NLRP3 Inflammasome: An Emerging Therapeutic Target for Alzheimer’s Disease
Tao, S., Fan, W., Liu, J., Wang, T., Zheng, H., Qi, G., Chen, Y., Zhang, H., Guo, Z., & Zhou, F. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230567 · Cited by 17
Yu, Q., Zhao, Y., Hu, X., Chen, X., Jiang, Y.-P., Jin, X.-J., Li, G., Li, Z.-H., Yang, J., Zhang, G.-L., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1390294 · Cited by 13
Therapeutic Targets in Innate Immunity to Tackle Alzheimer’s Disease
Serradas, M. L., Ding, Y., Martorell, P., Kulińska, I., & Castro‐Gomez, S. (2024) · Cells · doi:10.3390/cells13171426 · Cited by 16
Meng, F., Song, J., Huang, X., Zhang, M., Sun, X., Jing, Q., Cao, S., Xie, Z., Liu, Q., Zhang, H., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70049 · Cited by 13
Lin, Y., Cheng, L., Chen, Y., Li, W., Guo, Q., & Miao, Y. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00322.2024 · Cited by 13
Stem cell therapy in Alzheimer’s disease: current status and perspectives
Ou, C.-M., Xue, W.-W., Liu, D., Ma, L., Xie, H.-T., & Ning, K. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1440334 · Cited by 16
Liu, Y., Wang, Q., Ma, J., Li, J., Li, C., Xie, X., Xiao, Q., Xie, C., Liu, H. S., Hong, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02813 · Cited by 13
Wang, X., Liu, Y., Han, X., Zou, G., Zhu, W., Shen, H. C., & Liu, H. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128101 · Cited by 13
TSPO Ligands Protect against Neuronal Damage Mediated by LPS‐Induced BV‐2 Microglia Activation
Ma, B., Liu, Y., Xiao, Z., Zhang, R., Zhang, Z., Zhang, Z., Liu, J., Juan, Z., Sun, X., Sun, L., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5896699 · Cited by 15
Wei, J., Ma, X., Nehme, A., Cui, Y., Zhang, L., & Qiu, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.954266 · Cited by 13
The inflammasome in biomaterial‐driven immunomodulation
Vasconcelos, D. P., Águas, A. P., & Barbosa, J. N. (2022) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3361 · Cited by 13
An Altered Neurovascular System in Aging-Related Eye Diseases
Choi, Y. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214104 · Cited by 15
A novel strategy for bioactive natural products targeting NLRP3 inflammasome in Alzheimer’s disease
Yang, Z., Liu, J., Wei, S., Deng, J., Feng, X., Liu, S., & Liu, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077222 · Cited by 17
The effects of N6-methyladenosine RNA methylation on the nervous system
Shao, N., Ye, T., Xuan, W.-T., Zhang, M., Chen, Q., Liu, J., Zhou, P., Song, H., & Cai, B. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04691-6 · Cited by 14
Advances in proteomic phenotyping of microglia in neurodegeneration
Sunna, S. N., Bowen, C. A., Ramelow, C. C., Santiago, J. V., Kumar, P., & Rangaraju, S. (2023) · PROTEOMICS · doi:10.1002/pmic.202200183 · Cited by 13
Kadoya, H., Hirano, A., Umeno, R., Kajimoto, E., Iwakura, T., Kondo, M., Wada, Y., Kidokoro, K., Kishi, S., Nagasu, H., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202201777rrr · Cited by 13
Pollock, T. B., Cholico, G. N., Isho, N. F., Day, R., Suresh, T., Stewart, E. S., McCarthy, M. M., & Rohn, T. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00256 · Cited by 12
Loss of Homeostatic Microglia Signature in Prion Diseases
Wang, Y., Hartmann, K., Thies, E., Mohammadi, B., Altmeppen, H., Sepulveda-Falla, D., Glatzel, M., & Krasemann, S. (2022) · Cells · doi:10.3390/cells11192948 · Cited by 12
“It has been shown to play a fundamental role in Alzheimer’s disease (AD) pathophysiology [78,79].”
BackgroundKhezri, M. R., & Ghasemnejad-Berenji, M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220873 · Cited by 12
Zheng, X., Luo, Z., Zheng, J., Deng, C., Liu, D., Chen, Y., Zhou, R., Zou, J., Huang, G., Zeng, Q., et al. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70497 · Cited by 12
Kang, X., Tian, J., Shu, Q., Cheng, T., Wang, S., & Hu, Y. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.019 · Cited by 12
Peripheral immune and metabolic regulation of Aβ and Tau by exercise in Alzheimer’s disease
Yu, Y., & Chen, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1678526 · Cited by 14
Beyond microtubule regulation: the multifaceted roles of tau in neuronal function and dysfunction
Bakota, L., Tulva, K., Trushina, N. I., & Brandt, R. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03947-1 · Cited by 12
Mohamadzadeh, O., Hajinouri, M., Moammer, F., Zadeh, S. S. T., Shafiei, G. O., Jafari, A., Ostadian, A., Talaei, S. A., Hamblin, M. R., Yazdi, A. J., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03321-y · Cited by 12
Demuth, H., Hosseini, S., Düsedau, H. P., Dunay, I. R., Körte, M., & Zagrebelsky, M. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1163087 · Cited by 11
Lok, H. C., Katzeff, J. S., Hodges, J. R., Piguet, O., Fu, Y., Halliday, G. M., & Kim, W. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-35945-4 · Cited by 12
Casali, E., Serapian, S. A., Gianquinto, E., Castelli, M., Bertinaria, M., Spyrakis, F., & Colombo, G. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125609 · Cited by 12
pH-responsive Chinese herbal microneedles for acne therapy: A groundbreaking approach to skincare
Xin, H., Chen, Q., Zhou, T., Song, G., Pan, L., Yang, M., Zou, X., Lv, Z., Xu, Y., Jin, X., et al. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105719 · Cited by 12
Zhu, Y., Chen, Y., & Zu, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05415-0 · Cited by 12
Zhang, W., Wu, C.-C., Ge, M.-M., Yuan, X.-M., Han, S.-Y., Zhao, F.-T., Zhang, X., Gao, F., Tian, Y.-K., Zhang, G., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110119 · Cited by 12
Intracellularly manipulable aggregation of the aggregation-induced emission luminogens
Wang, W., Xin, Z., Liu, D., Liu, Y. U., Liu, Y. U., Qiu, Z., Zhang, J., Alam, P., Cai, X., Zhao, Z., et al. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116800 · Cited by 13
Liu, D., Wu, W., Wang, T., Zhan, G., Zhang, Y., Gao, J., & Gong, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1365642 · Cited by 12
Shao, N., Ding, Z., Liu, F., Zhang, X., Wang, X., Hu, S., Ye, S., Wang, T., Si, W., & Cai, B. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04547-0 · Cited by 12
Anton, P. E., Maphis, N. M., Linsenbardt, D. N., & Coleman, L. G. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-81908-7_10 · Cited by 12
Lan, L., Chen, C.-Y., Wang, Y., Guo, Z., & Zhang, Y. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111401 · Cited by 13
Candidate mechanisms linking insomnia disorder to Alzheimer’s disease risk
Chappel-Farley, M. G., Lui, K. K., Dave, A., Chen, I. Y., & Mander, B. A. (2020) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2020.01.010 · Cited by 12
A Peek into Pandora’s Box: COVID-19 and Neurodegeneration
Chandra, A., & Johri, A. (2022) · Brain Sciences · doi:10.3390/brainsci12020190 · Cited by 14
Wu, C., Qiu, T., Yuan, W., Shi, Y., Yao, X., Jiang, L., Zhang, J., Yang, G., Liu, X., Bai, J., et al. (2022) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2022.103981 · Cited by 12
Lv, J., Shen, X., Shen, X.-Y., Zhao, S., Xu, R., Yan, Q., Lu, J., Zhu, D., Zhao, Y., Dong, J., et al. (2023) · Phytotherapy Research · doi:10.1002/ptr.7945 · Cited by 12
Spreading of Tau Protein Does Not Depend on Aggregation Propensity
Rodrigues, S., Anglada‐Huguet, M., Hochgräfe, K., Kaniyappan, S., Wegmann, S., & Mandelkow, E. (2023) · Journal of Molecular Neuroscience · doi:10.1007/s12031-023-02143-w · Cited by 12
Zack, S. R., Venkatesan, M., Nikolaienko, R. M., Cook, B., Melki, R., Zima, A. V., & Campbell, E. M. (2024) · Inflammation Research · doi:10.1007/s00011-024-01856-x · Cited by 14
Yu, X., Yu, C., & He, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.952211 · Cited by 15
Guo, X., Zhang, G., Peng, Q., Liu, H., Ye, K., Xiao, T., Liu, C., Zhang, X., Li, S., Wang, H., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106158 · Cited by 12
Coburn, M., Eskandari‐Sedighi, G., Hasselmann, J., England, W., Shabestari, S. K., Mansour, K., McQuade, A., Mgerian, M., Chadarevian, J. P., Tu, C. H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70930 · Cited by 12
Neural stem cells fate under neuroinflammatory conditions and oxidative stress response
Torrisi, F., Denaro, S., Ragonese, J., D’Aprile, S., Zappalà, A., & Parenti, R. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1736865 · Cited by 12
Volonté, C., Hu, G., Shaw, C. A., Claudio, V. J., dos Santos, J. A., Vaz, S. H., Sebastião, A. M., Balcar, V. J., Mozley, P. D., Verde, F., et al. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004136 · Cited by 12
Huang, Z. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221042 · Cited by 12
Abdelmonem, M., Albert, E. L., Alhadad, M. A., & Abdullah, C. A. (2024) · Precision Nanomedicine · doi:10.33218/001c.92424 · Cited by 11
Basheer, N., Buée, L., Brion, J., Smolek, T., Muhammadi, M. K., Hritz, J., Hromádka, T., Dewachter, I., Wegmann, S., Landrieu, I., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01748-5 · Cited by 12
Self-citationYang, Y., Rao, T., Sheng, W., Cheng, J., Zhan, Y., Lin, T., Chen, J., Zhong, X., Jiang, Y., & Yang, S. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1398618 · Cited by 13
Amyloid-β-activated microglia can induce compound proteinopathies
Lee, S. H., Bae, E.-J., Pérez-Acuña, D., Jung, M. K., Han, J. W., Mook‐Jung, I., & Lee, S. (2024) · Brain · doi:10.1093/brain/awae221 · Cited by 11
C9orf72 dipeptides activate the NLRP3 inflammasome
Rivers‐Auty, J., Hoyle, C., Pointer, A., Lawrence, C. B., Pickering-Brown, S. M., Brough, D., & Ryan, S. (2024) · Brain Communications · doi:10.1093/braincomms/fcae282 · Cited by 11
Perdaens, O., & Pesch, V. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312637 · Cited by 12
Zhao, K., Zhang, Y., Liao, Z., Zhang, W.-F., Li, G., Shi, P., Cheng, Z., Chen, Y., Li, S., Wang, K., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202302453rrr · Cited by 11
Zhang, J., Zhang, Y., Liu, L., Zhang, M., Zhang, X., Deng, J., Zhao, F., Li, Q., Zheng, X., Fu, B., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03325-y · Cited by 12
Maphis, N. M., Hulse, J. P., Peabody, J., Dadras, S., Whelpley, M. J., Kandath, M., Wilson, C. M., Hobson, S., Thompson, J., Poolsup, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70101 · Cited by 10
Wang, W., Yang, T., Liu, N., Yang, L., Liu, C., Qi, X., Wang, N., Wang, M., & Wang, Y. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06763-5 · Cited by 14
Zhang, D.-Q., Li, G., Fu, Z.-D., Huang, Y., Feng, X., Chen, L., Wang, R., Zhao, W., & Li, Q. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110572 · Cited by 12
Gillet, J.-N. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.108046 · Cited by 11
Magnetic Resonance Imaging in Tauopathy Animal Models
Ni, R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.791679 · Cited by 11
Chen, X., Huang, L., Cui, L., Xiao, Z., Xiong, X., & Chen, C. (2022) · The Journal of Physiology · doi:10.1113/jp283259 · Cited by 11
Maksour, S., & Ooi, L. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15885 · Cited by 12
Brain Pathology in COVID-19: Clinical Manifestations and Potential Mechanisms
Xu, Z., Wang, H., Jiang, S., Teng, J., Zhou, D., Chen, Z., Wen, C., & Xu, Z. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01110-0 · Cited by 10
Role of Tau protein in long COVID and potential therapeutic targets
Marwaha, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1280600 · Cited by 11
Metadata
- Authors
- Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., Griep, A., Santarelli, F., Brosseron, F., Opitz, S., Stunden, J., Merten, M., Kayed, R., Golenbock, D. T., Blum, D., Latz, E., Buée, L., & Heneka, M. T.
- Affiliations
- University Hospital Bonn (DE)
- German Center for Neurodegenerative Diseases (DE)
- The University of Texas Medical Branch at Galveston (US)
- University of Massachusetts Chan Medical School (US)
- Inserm (FR)
- Corresponding author
- Heneka, Michael T.
- ORCID
- Venue
- Nature
- Published
- 2019-11-20
- Volume
- 575
- Issue
- 7784
- Pages
- 669-673
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7324015
- OpenAlex
- W2990312754
- Semantic Scholar
- 6a9d745a33a2d013c621f57586d9d719671530a7
- Cited by
- 1,487
- References
- 28
- Citations by year
- 2026: 189 · 2025: 226 · 2024: 255 · 2023: 226 · 2022: 248 · 2021: 193 · 2020: 143 · 2019: 3
- FWCI
- 101.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (R01 AG059752-02)
- Agence Nationale de la Recherche (ANR-11-LABX-0009)
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- National Institutes of Health
- National Institute on Aging (R01AG059752, R01AG054025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, tau hyperphosphorylation, tau aggregation, neurofibrillary tangles, Alzheimer's disease, amyloid-beta, microglia, amyloid hypothesis, frontotemporal dementia, neuroinflammation, caspase-1, IL-1β
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Gene Expression Regulation, Humans, Mice, Inbred C57BL, Phosphorylation, tau Proteins, Microglia, Cyclin-Dependent Kinase 5, Mice, Inflammasomes, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
